REMDESIVIR INDUCED SINUS BRADYCARDIA IN A 53-YEAR-OLD WOMAN DURING THE TREATMENT OF COVID-19 INFECTION: A CASE REPORT

We report a case of a 53-year-old woman with severe COVID-19 infection. On the second day of her treatment with Remdesivir and other standard therapies, sinus bradycardia was noted, requiring atropine and dopamine. Workup excluded the secondary causes. A probable diagnosis of Remdesivir-induced bradycardia was made and thus, Remdesivir was discontinued. Her condition normalized after four days of discontinuing Remdesivir. Hence, the treating physicians must be aware of the cardiac adverse effects of Remdesivir.